Genmab A/S ADR (NQ: GMAB )

27.52 -0.17 (-0.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Genmab A/S ADR

< Previous 1 2 3 4 5 6 Next >
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating
On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier. 
Via Investor's Business Daily
3 Hot Stocks That Could Live Up to Their Lofty Valuations
These companies have long runways of growth ahead 
Via The Motley Fool
Is AbbVie Stock a Buy Now?
The pharmaceutical company prepared well as Humira approaches its patent cliff next year. 
Via The Motley Fool
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier. 
Via Investor's Business Daily
BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84
The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84. 
Via Investor's Business Daily
3 Hail Mary Plays to Bring Your Stock Portfolio Back From the Brink
You may have to take a shot on some riskier plays if you want to make up your portfolio's significant loss of yardage. 
Via The Motley Fool
HC Wainwright Is Bullish On This Multiple Myeloma Focused Stock
Via Benzinga
Where Genmab Stands With Analysts
  Genmab (NASDAQ:GMAB) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Genmab, BioNTech Join Forces For Cancer Immunotherapy Candidates
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 68 companies reached new 52-week highs. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  During Monday's session, 50 stocks hit new 52-week highs. 
Via Benzinga
Kura Oncology Stock Shows Improved Relative Strength; Still Shy Of Benchmark
In a welcome move, Kura Oncology stock saw its Relative Strength Rating improve from 69 to 75 on Wednesday. 
Via Investor's Business Daily
Amgen Stock Shows Market Leadership With Jump To 90 RS Rating
On Wednesday, Amgen stock hit a key technical milestone, with its Relative Strength Rating upgraded to 90, a rise from 78 the day before. 
Via Investor's Business Daily
BioCryst Pharmaceuticals Stock Shows Rising Relative Strength
On Monday, BioCryst Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 90 to 93. 
Via Investor's Business Daily
Pacira Pharmaceuticals Stock Shows Rising Relative Strength
On Friday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 69 to 73. 
Via Investor's Business Daily
Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment
Via Benzinga
Pain Therapeutics Stock Shows Rising Price Performance With Jump To 97 RS Rating
Pain Therapeutics sees its Relative Strength Rating enter the elite 90-plus level. 
Via Investor's Business Daily
Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90
Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99. 
Via Investor's Business Daily
Sage Therapeutics Stock Scores Relative Strength Rating Upgrade
On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98
Amylyx Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating improve to 98, up from 83 the day before. 
Via Investor's Business Daily
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Agios Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 65 to 93. 
Via Investor's Business Daily
Legend Biotech Stock Joins Elite Club Of Stocks With RS Ratings Over 90
On Thursday, Legend Biotech stock had its Relative Strength (RS) Rating upgraded to 91, up from 87 a day earlier. 
Via Investor's Business Daily
Golden Cross Appears Before Genmab Investors
If history is any guide, there may be good fortune ahead for shares of Genmab (NASDAQ:GMAB). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the... 
Via Benzinga
Intercept Pharmaceutical Stock Shows Market Leadership; Earns 92 RS Rating
On Tuesday, Intercept Pharmaceutical stock had its Relative Strength Rating upgraded to 92, up from 89 a day earlier. 
Via Investor's Business Daily
Relay Therapeutics Stock Shows Market Leadership With Jump To 94 RS Rating
Relay Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 84 to 94. 
Via Investor's Business Daily
Kymera Therapeutics Stock Scores Rising Relative Price Strength
Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94. 
Via Investor's Business Daily
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
AbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.